| Description | Budiodarone（ATI-2042）is a chemical analog of an antiarrhythmic drug and amiodarone. Budedalone is promising as an antiarrhythmic agent for the prevention of atrial fibrillation. |
| Synonyms | ATI2042, ATI-2042, ATI 2042 |
| molecular weight | 703.35 |
| Molecular formula | C27H31I2NO5 |
| CAS | 335148-45-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Buchwald P, Bodor N. Recent advances in the design and development of soft drugs. Pharmazie. 2014 Jun;69(6):403-13. Review. PubMed PMID: 24974571. 2. Ezekowitz MD, Nagarakanti R, Lubinski A, Bandman O, Canafax D, Ellis DJ, Milner PG, Ziola M, Thibault B, Hohnloser SH; PASCAL Investigators. A randomized trial of budiodarone in paroxysmal atrial fibrillation. J Interv Card Electrophysiol. 2012 Jun;34(1):1-9. doi: 10.1007/s10840-011-9636-3. Epub 2011 Dec 29. PubMed PMID: 22205496. 3. Mason PK, DiMarco JP. New pharmacological agents for arrhythmias. Circ Arrhythm Electrophysiol. 2009 Oct;2(5):588-97. doi: 10.1161/CIRCEP.109.884429. Review. PubMed PMID: 19843928. 4. Arya A, Silberbauer J, Teichman SL, Milner P, Sulke N, Camm AJ. A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology. Europace. 2009 Apr;11(4):458-64. doi: 10.1093/europace/eun384. Epub 2009 Jan 26. PubMed PMID: 19174378; PubMed Central PMCID: PMC2659603. |